Project Name：Dabigatran etexilate 

Registration Classification：3+6

Formulations and specifications ：Capsules: 110mg, 150mg 

Indications：For the prevention of total hip / knee replacement surgery DVT , reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation  .

Original Research Company：Boehringer Ingelheim 

Progress ：Pharmaceutical Research in progress